The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Risk of End‐Stage Renal Disease in Patients With Lupus Nephritis, 1971–2015: A Systematic Review and Bayesian Meta‐Analysis
Open accessAbstract
Objective: End‐stage renal disease (ESRD) is a major consequence of lupus nephritis, but how this risk has changed over time is unknown. We conducted this systematic review to examine changes in ESRD among adults with lupus nephritis from 1971 to 2015 and to estimate risks of ESRD among contemporary patients. Methods: We searched PubMed, Embase, and the Cochrane Database of Systematic Reviews for cohort studies and clinical trials on ESRD in adults with lupus nephritis. We analyzed studies from developed and developing countries separately. The outcome was probability of ESRD at 5, 10, and 15 years of lupus nephritis. Results: We included 187 articles that reported on 18,309 patients. In developed countries, the 5‐year risk of ESRD decreased from 16% (95% confidence interval [95% CI] 14–17%) in 1970–1979 to 11% (95% CI 10–12%) in the mid‐1990s and then plateaued. ESRD risks at 10 years and 15 years showed steeper declines in the 1970s and 1980s but also plateaued in 1993–1997, with a notable increase in the late 2000s. The decrease in risk after 1980 coincided with increased use of cyclophosphamide. The 15‐year ESRD risk was higher in developing countries than in developed countries. Patients with class IV lupus nephritis had the greatest risk of ESRD, with a 15‐year risk of 44% during the 2000s. Conclusion: Risks of ESRD in lupus nephritis improved between the 1970s and the mid‐1990s and then plateaued, with an increase in the late 2000s. This pattern suggests limitations in the effectiveness of, or access to, current treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
(2014) · Medical Entomology and Zoology · Cited by 17,633
Guyot, P., Ades, A., Ouwens, M. J., & Welton, N. J. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-9 · Cited by 2,526
Wang, P. S., Aguilar-Gaxiola, S., Alonso, J., Angermeyer, M. C., Borges, G., Bromet, E. J., Bruffaerts, R., de Girolamo, G., de Graaf, R., Gureje, O., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61414-7 · Cited by 1,655 · cited 1×
“This classification has been used previously in studies of global differences in health outcomes (26,27).”
MethodHahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daikh, D. I., FitzGerald, J. D., Karpouzas, G. A., Merrill, J. T., Wallace, D. J., Yazdany, J., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21664 · Cited by 1,463
Cervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., Lavilla, P., Mejía, J. C., Aydintug, A. O., Chwalinska-Sadowska, H., de Ramón, E., et al. (2003) · Medicine · doi:10.1097/01.md.0000091181.93122.55 · Cited by 1,377
Austin, H. A., Klippel, J. H., Balow, J. E., Le Riche, N. G. H., Steinberg, A. D., Plotz, P. H., & Decker, J. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141004 · Cited by 1,185
Bertsias, G. K., Tektonidou, M., Amoura, Z., Aringer, M., Bajema, I., Berden, J. H. M., Boletis, J., Cervera, R., Dörner, T., Doria, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201940 · Cited by 1,007
Self-citationCyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans
Dooley, M. A., Hogan, S., Jennette, C., Falk, R., & for the Glomerular Disease Collaborative Network (1997) · Kidney International · doi:10.1038/ki.1997.162 · Cited by 341
Changing Patterns in Mortality and Disease Outcomes for Patients with Systemic Lupus Erythematosus
UROWITZ, M. B., GLADMAN, D. D., TOM, B. D. M., IBAÑEZ, D., & FAREWELL, V. T. (2008) · The Journal of Rheumatology · doi:10.3899/jrheum.080214 · Cited by 327
Survival analysis and causes of mortality in patients with lupus nephritis
Yap, D. Y. H., Tang, C. S. O., Ma, M. K. M., Lam, M. F., & Chan, T. M. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs073 · Cited by 319
Teo, K., Lear, S., Islam, S., Mony, P., Dehghan, M., Li, W., Rosengren, A., Lopez-Jaramillo, P., Diaz, R., Oliveira, G., et al. (2013) · JAMA · doi:10.1001/jama.2013.3519 · Cited by 305
Long-term follow-up of patients with lupus nephritis
Appel, G. B., Cohen, D. J., Pirani, C. L., Meltzer, J. I., & Estes, D. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90645-0 · Cited by 278
Morbidity of systemic lupus erythematosus: Role of race and socioeconomic status
Petri, M., Perez-Gutthann, S., Longenecker, J. C., & Hochberg, M. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90151-m · Cited by 278
Mortality and causes of death in systemic lupus erythematosus
Trager, J., & Ward, M. M. (2001) · Current Opinion in Rheumatology · doi:10.1097/00002281-200109000-00002 · Cited by 264
Self-citationFelson, D. T., & Anderson, J. (1984) · New England Journal of Medicine · doi:10.1056/nejm198412133112402 · Cited by 233
Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions
Ortega, L., Schultz, D., Lenz, O., Pardo, V., & Contreras, G. (2010) · Lupus · doi:10.1177/0961203309358187 · Cited by 219
Fiehn, C., Hajjar, Y., Mueller, K., Waldherr, R., Ho, A. D., & Andrassy, K. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.5.435 · Cited by 197
Prognostic determinants in lupus nephritis: a long-term clinicopathologic study
Donadio, J., Hart, G., Bergstralh, E., & Holley, K. (1995) · Lupus · doi:10.1177/096120339500400206 · Cited by 195
Depression, medication adherence, and service utilization in systemic lupus erythematosus
Julian, L. J., Yelin, E., Yazdany, J., Panopalis, P., Trupin, L., Criswell, L. A., & Katz, P. (2009) · Arthritis Care & Research · doi:10.1002/art.24236 · Cited by 192
Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking
Ward, M. M. (1992) · Archives of Internal Medicine · doi:10.1001/archinte.152.10.2082 · Cited by 184
Self-citationThe long-term outcome of 93 patients with proliferative lupus nephritis
Moroni, G., Quaglini, S., Gallelli, B., Banfi, G., Messa, P., & Ponticelli, C. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm245 · Cited by 173
Unmet medical needs in systemic lupus erythematosus
Lateef, A., & Petri, M. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3919 · Cited by 152
Socioeconomic Status and the Incidence of ESRD
Ward, M. M. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.11.023 · Cited by 140
Self-citationHenderson, L., Masson, P., Craig, J. C., Flanc, R. S., Roberts, M. A., Strippoli, G. F., & Webster, A. C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002922.pub3 · Cited by 131
Clinical Prognostic Factors in Lupus Nephritis
Ward, M. M. (1992) · Archives of Internal Medicine · doi:10.1001/archinte.1992.00400220098017 · Cited by 130
Self-citationLi, T. M. W. Y., Carls, G. S., Panopalis, P., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24545 · Cited by 118
Time to Renal Disease and End-Stage Renal Disease in PROFILE: A Multiethnic Lupus Cohort
Alarcón, G. S., McGwin, G., Petri, M., Ramsey‐Goldman, R., Fessler, B. J., Vilá, L. M., Edberg, J. C., Reveille, J. D., Kimberly, R. P., & for the PROFILE Study Group (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030396 · Cited by 108
The Time‐Dependence of Long‐Term Prediction in Lupus Nephritis
Esdaile, J. M., Abrahamowicz, M., MacKenzie, T. A., Hayslett, J. P., & Kashgarian, M. J. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370309 · Cited by 91
Jurkovitz, C. T., Li, S., Norris, K. C., Saab, G., Bomback, A. S., Whaley‐Connell, A. T., & McCullough, P. A. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.12.015 · Cited by 60
Dolff, S., Berden, J. H. M., & Bijl, M. (2010) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.79 · Cited by 15
Cited by
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Furie, R., Rovin, B. H., Houssiau, F., Malvar, A., Teng, Y. K. O., Contreras, G., Amoura, Z., Yu, X., Mok, C.-C., Santiago, M. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001180 · Cited by 1,032
Almaani, S., Meara, A., & Rovin, B. H. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05780616 · Cited by 930
The immune cell landscape in kidneys of patients with lupus nephritis
the Accelerating Medicines Partnership in SLE network, Arazi, A., Rao, D. A., Berthier, C. C., Davidson, A., Liu, Y., Hoover, P. J., Chicoine, A., Eisenhaure, T. M., Jonsson, A. H., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0398-x · Cited by 827
Fanouriakis, A., Kostopoulou, M., Cheema, K., Anders, H.-J., Aringer, M., Bajema, I., Boletis, J., Frangou, E., Houssiau, F. A., Hollis, J., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-216924 · Cited by 825
Management strategies and future directions for systemic lupus erythematosus in adults
Durcan, L., O'Dwyer, T., & Petri, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30237-5 · Cited by 648
Metadata
- Authors
- Tektonidou, M. G., Dasgupta, A., & Ward, M. M.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2016-05-26
- Volume
- 68
- Issue
- 6
- Pages
- 1432-1441
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2298285162
- Cited by
- 582
- References
- 33
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.